http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1211258-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f07293d4b34d8372fb0775181fef9d23
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D337-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D313-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D337-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D313-08
filingDate 1968-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1970-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-1211258-A
titleOfInvention Amines
abstract 1,211,258. Amines. BOEHRINGER INGELHEIM G.m.b.H. 1 Feb., 1968 [1 Feb., 1967; 2 June, 1967; 19 July, 1967], No. 5295/68. Heading C2C. Racemic and optically active cis, trans and cis-trans compounds of the general Formula (I) (R 1,2 = H, halogen, Me, OMe, CF 3 , CN, OH or R 1+2 together with the adjacent ring = naphthalene, indane, tetrahydronaphthalene, benz-1,3-dioxole or benzodioxane ring system; R 3 = H, Me, Et, Ph optionally substituted by at least one methyl group; R 4 = H, Me, Et, Ph optionally substituted by halogen, Me, OMe; R 5 = H, C 1-3 alkyl, PhCH 2 optionally substituted by halogen and/or C 1-3 alkyl; R 6 = H, C 1-3 alkyl or -NR 5 R 6 = pyrrolidino, piperidino, morpholino or 5-6 membered ring containing a further nitrogen atom optionally N-substituted by Me, Et, Ph optionally substituted by at least one halogen and/or Me and/or Et; X = O, S, CH 2 provided that when X = O and R 1,2 = 7- and 8-Me, at least one of R 3-6 is not H and when X = S at least one of R 1-6 is not H) and their acid addition salts are prepared by (a) reacting a compound of the Formula (II) with a reducing agent whereby the ketonic oxyten atom is converted to an OH group with simultaneous introduction of R 3 , (b) alkylating or benzylating a compound of the Formula (I) in which R 5,6 = H, or (c) hydrolysing or hydrogenolysing a compound of the Formula (IV) (R<SP>1</SP> = protecting group), optionally followed in each case by salt formation and/or separation of the racemates of the cis and trans isomers and in the latter case by resolution. The above compounds are antidepressants and anticonvulsants, and may be administered in the form of pharmaceutical preparations containing them in association with a carrier.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6262277-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6420417-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6740663-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6462091-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5994391-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7019023-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6107494-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6458851-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6569905-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6458850-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6943189-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6489366-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6642268-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6586434-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0116372-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6562860-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0116373-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0781278-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11229661-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4845094-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2600332-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11376251-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6638969-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10512657-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6890958-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-1110494-C
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1440972-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6642269-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9733882-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-723123-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6268392-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6852753-B2
priorityDate 1967-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425199706
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408141350
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID931
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407740905
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504459
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3826
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8404
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457444288
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10326
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412478856
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9229
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10301
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419511497

Total number of triples: 60.